Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E62.24 EPS (ttm)8.31 Insider Own1.10% Shs Outstand105.38M Perf Week12.49%
Market Cap54.52B Forward P/E33.91 EPS next Y15.26 Insider Trans-4.30% Shs Float78.23M Perf Month12.89%
Income963.10M PEG3.27 EPS next Q3.12 Inst Own71.40% Short Float3.50% Perf Quarter38.69%
Sales4.98B P/S10.95 EPS this Y39.50% Inst Trans-0.92% Short Ratio2.77 Perf Half Y41.71%
Book/sh46.09 P/B11.22 EPS next Y20.41% ROA13.80% Target Price461.10 Perf Year44.85%
Cash/sh12.40 P/C41.71 EPS next 5Y19.01% ROE21.50% 52W Range325.35 - 543.55 Perf YTD40.93%
Dividend- P/FCF38.92 EPS past 5Y38.80% ROI18.20% 52W High-4.82% Beta1.68
Dividend %- Quick Ratio2.60 Sales past 5Y61.30% Gross Margin94.50% 52W Low59.01% ATR15.91
Employees5400 Current Ratio2.80 Sales Q/Q9.80% Oper. Margin28.80% RSI (14)71.18 Volatility4.90% 2.94%
OptionableYes Debt/Eq0.15 EPS Q/Q36.20% Profit Margin19.30% Rel Volume1.91 Prev Close526.53
ShortableYes LT Debt/Eq0.14 EarningsAug 03 BMO Payout0.00% Avg Volume988.05K Price517.33
Recom2.20 SMA208.47% SMA5018.24% SMA20031.42% Volume1,885,329 Change-1.75%
Jun-20-17Reiterated Piper Jaffray Overweight $446 → $557
May-05-17Upgrade Canaccord Genuity Hold → Buy $375 → $484
Mar-29-17Reiterated UBS Buy $435 → $446
Mar-17-17Initiated Oppenheimer Perform
Mar-09-17Initiated UBS Buy $435
Feb-16-17Downgrade Goldman Buy → Neutral
Jan-06-17Reiterated RBC Capital Mkts Outperform $626 → $598
Jan-06-17Reiterated Chardan Capital Markets Neutral $350 → $345
Dec-20-16Upgrade Credit Suisse Neutral → Outperform
Dec-12-16Upgrade Chardan Capital Markets Sell → Neutral $300 → $350
Nov-07-16Reiterated Chardan Capital Markets Sell $325 → $300
Aug-05-16Downgrade Robert W. Baird Outperform → Neutral $505 → $448
Jun-29-16Initiated Bernstein Outperform
Apr-20-16Downgrade Wells Fargo Outperform → Market Perform
Mar-28-16Reiterated Canaccord Genuity Hold $525 → $450
Mar-17-16Reiterated Sun Trust Rbsn Humphrey Neutral $450 → $410
Mar-16-16Downgrade Chardan Capital Markets Neutral → Sell $375 → $325
Mar-15-16Initiated Gabelli & Co Buy $574
Mar-03-16Initiated Sun Trust Rbsn Humphrey Neutral $450
Feb-25-16Initiated Citigroup Buy $480
Jun-23-17 09:00PM  On Not Talking About the 'Market'; Darth Vader, Meet Amazon: Jim Cramer's Best Blog
05:14PM  Sonic, Forestar post gains; BlackBerry, Regeneron fall Associated Press
04:36PM  Week In Review: Biotechs, Software Drive Nasdaq; Boeing Tops Airbus; Oil Hit Investor's Business Daily
04:14PM  Biotechs Hit Pause On 5-Day Rally As Regeneron, Bluebird Topple Investor's Business Daily
10:08AM  Biotech Movers: Regeneron Slides Back After Big Gains
09:38AM  Regeneron (REGN) Stock on Fire: What's Behind the Surge? Zacks
Jun-22-17 04:27PM  After Celgene, Regeneron Breakouts, This Biotech Stock May Be Next Investor's Business Daily
04:05PM  Why The Biotech Rally Could Still Tack On Another 15% Upside Investor's Business Daily
03:42PM  If Esperion Wants to Market the Next Big Cholesterol Drug, It Will Take Strategy Motley Fool
01:30PM  2 Key Stock Index Plays In Buy Range As Biotechs Surge Again Investor's Business Daily
12:22PM  Health-Care Stocks Get a Boost From Senate Bill Rollout The Wall Street Journal
12:11PM  Stock Indexes Grip Small Gains, But This New Leader Swings Higher Investor's Business Daily
11:36AM  Regeneron: How High Can It Go?
10:03AM  Indivor's Opioid Use Disorder Drug Meets Primary Endpoint Zacks
08:59AM  Regeneron Details Royalty Agreement with Novartis for Canakinumab (ACZ885) PR Newswire
08:35AM  AveXis (AVXS) Jumps: Stock Rises 7.1% Zacks
08:30AM  Strength Seen in Arena Pharmaceuticals (ARNA): Stock Up 5.4% Zacks
06:48AM  Futures: These 2 Big Breakouts Highlight New Market Leadership Investor's Business Daily
Jun-21-17 06:12PM  Cramer finds where the real growth is in a split market CNBC +5.39%
05:48PM  Finding real growth in a split market CNBC Videos
05:08PM  Technician: Forget tech, keep buying health-care stocks CNBC Videos
04:11PM  Biotech Breakouts: Biogen Spinoff Bioverativ In Buy Zone Investor's Business Daily
03:45PM  Nasdaq Leads Again; Are These 3 Stocks The Next Apple In Biotech Land? Investor's Business Daily
08:30AM  Vanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8% Zacks
08:30AM  Regeneron Recognized on "The Civic 50" List of the Most Community-Minded Companies in the United States PR Newswire
08:00AM  Today's Research Reports on Stocks to Watch: Regeneron Pharmaceuticals and Alexion Pharmaceuticals Accesswire
07:36AM  Kevzara Could Be a Robust Growth Opportunity for Regeneron Market Realist
Jun-20-17 05:50PM  Regeneron Soars After Eye Drug Competitor Novartis Releases Positive Data +5.02%
04:45PM  Could Novartis' Drug Topple Regeneron's Blockbuster Eylea? Investor's Business Daily
04:43PM  These Biotechs Are Leading The Sector To A 3-Month High Today Investor's Business Daily
04:25PM  The (Second) Hottest Stock: Regeneron Pharmaceuticals Jumps 5%
04:21PM  Novartis Takes Aim at Regeneron Pharmaceuticals' Eylea Motley Fool
04:17PM  Stocks End Lower As Oil Takes Toll; Drugmakers A Bright Spot Investor's Business Daily
03:36PM  Eosinophilic Esophagitis: Major Market Opportunity for Dupixent? Market Realist
03:05PM  Nasdaq Falls, Dow Holds Up; Biotechs On Fire As Oil Slumps Again Investor's Business Daily
02:30PM  Novartis eye drug works with fewer injections than rival Reuters
02:06PM  Dupixent May Prove Effective in Multiple Diseases Market Realist
12:20PM  Label Expansion May Boost Regenerons Dupixent in the Future Market Realist
12:09PM  Regeneron stock surges 7% after Novartis releases positive data for rival drug MarketWatch
10:56AM  The Eyes Have It! Why Regeneron Is Hitting A 52-Week High
10:33AM  Merrimack Completes Enrollment in Phase II Study for MM-141 Zacks
09:30AM  CAI International, Kroger, Broadcom, Regeneron and Vodafone Group highlighted as Zacks Bull and Bear of the Day Zacks
09:07AM  Dupixent May Be a Major Growth Driver for Regeneron in 2017 Market Realist
08:29AM  UPDATE 1-Novartis eye drug works with fewer injections than rivals Reuters
07:36AM  Regenerons Praluent May See Gradual Increase in 2017 Demand Market Realist
04:30AM  Novartis eye drug works at less frequent dosing than rival's Reuters
Jun-19-17 11:11AM  Biogen: "The Underperformance Stops Here"
10:37AM  Regeneron Continues to Explore Eylea in Multiple New Indications Market Realist
09:08AM  Eylea Continues to Be a Key Growth Driver for Regeneron in 2017 Market Realist
07:37AM  Regeneron Expected to Report Healthy Revenue Growth in 2017 Market Realist
Jun-16-17 05:13PM  Analysts Recommendations for Regeneron and Peers in June 2017 Market Realist
01:06PM  Biotech Stocks To Watch And Pharma Industry News Investor's Business Daily
07:37AM  5 best bets in biotech: Expert CNBC Videos
Jun-15-17 02:36PM  Regeneron: Coming Up Roses?
01:10PM  These Leading Stocks Fuel This Hot Janus Henderson Mutual Fund Investor's Business Daily
Jun-14-17 09:30AM featured highlights: Regeneron Pharmaceuticals, Raymond James Financial, Dollar General, Xcel Energy and Morgan Stanley Zacks
08:17AM  The SPDR S&P Biotech (ETF) (XBI) Is on Breakout Watch InvestorPlace
Jun-13-17 10:14AM  GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up Zacks
08:58AM  Lilly Plans New Outcomes Study to Expand Jardiance Label Zacks
Jun-12-17 04:12PM  Is Regeneron, Sanofi's Eczema Drug Headed For Blockbuster Status? Investor's Business Daily
03:51PM  J&J Announces EU Regulatory Approval for Actelion Deal Zacks
11:25AM  Regeneron: Forget Praluent. This Is the Drug That Really Matters.
08:49AM  Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies Zacks
Jun-11-17 11:38AM  Sanofi-Regeneron's Praluent cuts cholesterol in Odyssey trials Reuters
11:03AM  Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia GlobeNewswire
11:00AM  Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia PR Newswire
Jun-10-17 12:01AM  [$$] Stick With Regeneron
Jun-09-17 06:26AM  Regeneron (REGN) Up 7.3% Since Earnings Report: Can It Continue? Zacks
Jun-08-17 10:44AM  AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan Zacks
Jun-07-17 08:45PM  One Insider Just Bought $65 Million Worth of This Expensive Biotech Stock
05:42PM  Acorda Presents Phase III Data on PD Candidate CVT-301 Zacks
04:22PM  Will Regeneron's Cholesterol-Buster Get Booted In Amgen Battle? Investor's Business Daily
01:32PM  Will Regeneron's Cholesterol-Buster Get Booted In Amgen Battle? Investor's Business Daily
11:40AM  Amgen: It Could Win The Latest Patent Battle; Will It Matter?
10:16AM  Pfizer's (PFE) Tafamidis Gets Fast Track Status in the U.S. Zacks
Jun-06-17 05:41PM  Regeneron, Sanofi urge court to reverse ban on cholesterol drug Reuters
03:03PM  Regeneron vs Amgen: Does The Patent Battle Even Matter?
Jun-05-17 10:35AM  Regeneron Announces Positive Data on Carcinoma Candidate Zacks
08:01AM  Why Regeneron Is Quickly Becoming My Top Biotech Stock Pick Motley Fool
Jun-04-17 11:41AM  3 Biotech Stocks to Buy If You've Never Bought a Biotech Stock Motley Fool
10:00AM  Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
10:00AM  Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
Jun-02-17 03:41PM  What's Behind Regeneron's Big 15% Bounce in May? Motley Fool
01:25PM  Chips Lead Nasdaq Higher, But Check Out This Biotech On The Move Investor's Business Daily
09:30AM  Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day Zacks
Jun-01-17 02:56PM  Eli Lilly's (LLY) Cancer Drug Cyramza Positive in Phase III Zacks
09:08AM  3 Hot Biotech Stocks to Buy in June Zacks
08:02AM  Has The Final Piece To Eliminate Heart Disease Been Discovered? Probably Not Forbes
May-31-17 06:28PM  3 Hot Stocks to Buy in May Motley Fool
11:48AM  Pfizer's Trumenba Vaccine Approved by European Commission Zacks
11:46AM  Merck's HIV Drug Isentress Gets FDA Approval for Higher Dose Zacks
10:25AM  Perrigo's (PRGO) Q1 Earnings Beat Estimates, Guidance Intact Zacks
09:15AM  How Regeneron Pharmaceuticals, Inc. Makes Most of Its Money Motley Fool
May-30-17 10:07AM  Will Regeneron's (REGN) Newly Approved Drugs Drive Growth? Zacks
08:37AM  5 stocks beyond Amazon that are ripe for a share split MarketWatch
May-27-17 08:00AM  Which Biotechs Benefit Most Under Trump's Tax Reform Vision? Investor's Business Daily
May-26-17 04:20PM  Are Regeneron, Sanofi Treading On Pfizer In Eczema? Investor's Business Daily
May-25-17 10:27AM  Regeneron Presents Positive Phase II Data on HoFH Candidate Zacks
09:30AM  The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene Zacks
May-24-17 05:00PM  Regeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive Phase 2 Data in People with HoFH PR Newswire
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children's. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor, as well as collaboration agreement with Intellia Therapeutics, Inc., to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STAHL NEILEVP Research and DevelopmentJun 22Sale532.558,3064,423,33223,950Jun 23 04:09 PM
Aberman Michael SSVP Strategy Investor RelationJun 22Sale532.422,2691,208,0614,693Jun 23 04:10 PM
STAHL NEILEVP Research and DevelopmentJun 21Option Exercise30.6320,000612,60043,950Jun 23 04:09 PM
Aberman Michael SSVP Strategy Investor RelationJun 21Option Exercise30.634,500137,8359,193Jun 23 04:10 PM
BROWN MICHAEL SDirectorJun 20Option Exercise177.823,000533,4603,000Jun 21 04:11 PM
GOLDSTEIN JOSEPH LDirectorJun 20Option Exercise273.671,000273,67014,000Jun 21 04:12 PM
BROWN MICHAEL SDirectorJun 20Sale500.003,0001,500,0000Jun 21 04:11 PM
GOLDSTEIN JOSEPH LDirectorJun 20Sale500.011,000500,01013,000Jun 21 04:12 PM
Terifay Robert JEVP CommercialJun 16Sale468.1921,1479,900,81423,293Jun 19 04:44 PM
Terifay Robert JEVP CommercialJun 15Option Exercise52.0348,7502,536,46372,043Jun 19 04:44 PM
STAHL NEILEVP Research and DevelopmentJun 15Sale468.458,5674,013,17723,950Jun 16 04:36 PM
STAHL NEILEVP Research and DevelopmentJun 14Option Exercise21.2520,295431,26944,245Jun 16 04:36 PM
BROWN MICHAEL SDirectorJun 12Option Exercise177.822,000355,6402,000Jun 14 04:36 PM
BROWN MICHAEL SDirectorJun 12Sale474.452,000948,8900Jun 14 04:36 PM
GOLDSTEIN JOSEPH LDirectorJun 09Option Exercise273.671,000273,67014,000Jun 13 05:06 PM
GOLDSTEIN JOSEPH LDirectorJun 09Sale482.551,000482,55013,000Jun 13 05:06 PM
STAHL NEILEVP Research and DevelopmentJun 02Sale479.492,8121,348,31423,950Jun 05 04:52 PM
STAHL NEILEVP Research and DevelopmentJun 01Option Exercise198.3810,5442,091,72430,814Jun 05 04:52 PM
VAGELOS P ROYChairman of the BoardMay 25Sale458.149,2954,258,37383,652May 26 04:04 PM
BROWN MICHAEL SDirectorMay 12Option Exercise177.823,000533,4603,000May 15 04:07 PM
BROWN MICHAEL SDirectorMay 12Sale450.003,0001,350,0000May 15 04:07 PM
BROWN MICHAEL SDirectorMar 29Option Exercise177.821,000177,8201,000Mar 30 04:42 PM
BROWN MICHAEL SDirectorMar 29Sale400.001,000400,0000Mar 30 04:42 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 15Option Exercise20.32195,0793,964,005697,000Dec 19 04:09 PM
SCHLEIFER LEONARD SPresident & CEODec 15Option Exercise20.32250,0005,080,000292,806Dec 19 04:07 PM
BAKER CHARLES ADirectorDec 12Option Exercise18.613,00055,83012,000Dec 14 05:41 PM
BAKER CHARLES ADirectorDec 12Sale392.023,0001,176,0489,000Dec 14 05:41 PM
RYAN ARTHUR FDirectorNov 15Sale429.342,000858,68036,500Nov 16 04:21 PM
GOLDSTEIN JOSEPH LDirectorNov 14Option Exercise273.672,125581,54915,125Nov 15 04:08 PM
GOLDSTEIN JOSEPH LDirectorNov 14Sale450.002,125956,25013,000Nov 15 04:08 PM
VAGELOS P ROYChairman of the BoardNov 07Option Exercise20.3276,8951,562,506515,726Nov 09 04:10 PM
GOLDSTEIN JOSEPH LDirectorJul 29Option Exercise273.672,125581,54915,125Aug 01 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 29Sale425.002,125903,12513,000Aug 01 04:04 PM